This is evident in obese NAFLD patients with impaired insulin sensitivity, hyperlipidemia, and liver injury, having lower circulating ketone bodies (Fletcher et al., 2019). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.